254 completed, 50 unknown, 32 recruiting, 25 terminated. 87 Phase 2, 73 Phase 1, 64 Not applicable, 54 Phase 3, 38 Phase 4.
Follow Cytomegalovirus Infections: new trials by email Literature Review of Cytomegalovirus Infections trials Research Report on Cytomegalovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in Argentina Cytomegalovirus Infections, Solid Organ Transplantation Recipient | Not yet recruiting | Hospital Italiano de Buenos Aires | 200 | 2026-09-01 | 2026-08-26 | |
| Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone Standard of Care Antiviral medications, Viral CTLs - CMV, AdV Infection | Phase 3 | Recruiting | New York Medical College | 138 | 2026-09-01 | 2026-09-11 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| CMV-CMI in csCMVi After HSCT Anti-Cytomegalovirus Therapy - Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2026-06-01 | 2026-07-07 | |
| Letermovir vs Valganciclovir in CMV R+ Kidney Transplant Letermovir, Valganciclovir CMV Prophylaxis - CMV Infection, CMV | Phase 4 | Not yet recruiting | Elisabeth Kincaide | 300 | 2026-05-01 | 2026-05-08 |
| Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis. LB-DTK-CMV - CMV Retinitis | Not applicable | Recruiting | LucasBio | 5 | 2026-04-27 | 2026-07-01 |
| Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection Congenital Cytomegalovirus, Cytomegalovirus Infections | Recruiting | Copenhagen University Hospital, Rigshospitalet | 630 | 2026-04-21 | 2026-06-09 | |
| HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial 50% reduction in the dose of MPA, Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus, standard antiviral therapy along with maintenance of their initial immunosuppressive therapy. - CMV Infection | Phase 4 | Not yet recruiting | Oriol Manuel | 100 | 2026-04-01 | 2026-05-06 |
| Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission SYN002 - Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient | Early Phase 1 | Not yet recruiting | University Health Network, Toronto | 12 | 2026-03-16 | 2026-03-23 |
| Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration CMV Infection | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1114 | 2026-03-14 | 2026-03-02 | |
| Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection Intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily) was administered for a treatment course of 4 months., Patients received a 6-month course of anti-CMV therapy. The treatment regimen consisted of either intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily). - Congenital CMV Infection | Phase 4 | Not yet recruiting | Hu Bofei | 150 | 2026-02-15 | 2026-03-04 |
| Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation. LB-DTK-MV - BKV Infection, CMV Infection | Not applicable | Recruiting | LucasBio | 6 | 2026-02-10 | 2026-07-06 |
| ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse Valganciclovir, Placebo - Cytomegalovirus (CMV) Infection | Phase 2 | Not yet recruiting | Wits Health Consortium (Pty) Ltd | 130 | 2026-02-01 | 2026-01-30 |
| Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. LB-DTK-MV - BKV Infection, EBV Infection | Phase 1 / Phase 2 | Recruiting | LucasBio | 27 | 2025-12-04 | 2026-06-26 |
| Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study Valacyclovir (Valtrex), Valganciclovir (Valcyte) - Kidney Transplantation, Cytomegalovirus Infections, EBV Infection | Not applicable | Recruiting | National Taiwan University Hospital | 80 | 2025-11-27 | 2025-12-19 |
| Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT. CMV-Specific T-cell Guided Letermovir Discontinuation, Standard Letermovir Prophylaxis - Cytomegalovirus Infections, Cytomegalovirus Disease | Phase 4 | Recruiting | WeiShi | 120 | 2025-10-30 | 2026-06-01 |
| HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation | Not yet recruiting | Ting YANG | 300 | 2025-10-10 | 2025-10-07 | |
| CMV-associated Immunomodulation in Renal Transplant Patients blood sampling - Kidney Transplantation | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2025-10-01 | 2025-09-12 |
| A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection maribavir - Infections, Cytomegalovirus | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 17 | 2025-09-25 | 2025-08-26 |
Showing 20 of 401. Sign in to see all of them.
HIV Infections (84) · Acquired Immunodeficiency Syndrome (68) · Cytomegalovirus Retinitis (64) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (47) · Retinitis (37) · AIDS-Related Opportunistic Infections (33) · Adenoviridae Infections (24) · Epstein-Barr Virus Infections (24) · Virus Diseases (16) · Infections (11) · Hearing Loss, Sensorineural (8) · Hematologic Neoplasms (7) · Hodgkin Disease (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7)
DNA Virus Infections (395) · Herpesviridae Infections (395) · Infections (390) · Virus Diseases (385) · Immune System Diseases (108) · Urogenital Diseases (102) · Genital Diseases (96) · Communicable Diseases (94) · RNA Virus Infections (94) · Sexually Transmitted Diseases (93) · Immunologic Deficiency Syndromes (92) · Blood-Borne Infections (91) · Lentivirus Infections (90) · Retroviridae Infections (90) · Sexually Transmitted Diseases, Viral (90)
Ganciclovir (58) · Valganciclovir (45) · letermovir (21) · Foscarnet (19) · Blood Specimen Collection (10) · Cidofovir (10) · Mycophenolic Acid (10) · Everolimus (8) · mRNA-1647 cytomegalovirus vaccine (8) · Valacyclovir (6) · Zidovudine (6) · sevirumab (6) · Probenecid (5) · cytomegalovirus-specific hyperimmune globulin (5) · maribavir (5)
National Institute of Allergy and Infectious Diseases (NIAID) (47) · Hoffmann-La Roche (23) · Assistance Publique - Hôpitaux de Paris (12) · National Heart, Lung, and Blood Institute (NHLBI) (10) · City of Hope Medical Center (9) · ModernaTX, Inc. (8) · Astra USA (6) · Johns Hopkins Bloomberg School of Public Health (6) · Merck Sharp & Dohme LLC (6) · Baylor College of Medicine (5) · GlaxoSmithKline (5) · The First Affiliated Hospital of Soochow University (5) · University Hospital, Bordeaux (5) · AlloVir (4) · Fondazione IRCCS Policlinico San Matteo di Pavia (4)
United States (199) · France (47) · United Kingdom (27) · Spain (26) · China (25) · Canada (20) · Italy (18) · Germany (16) · Belgium (15) · Australia (12) · Brazil (12) · Israel (8) · Mexico (8) · South Korea (7) · Switzerland (7)
Helen E Heslop, MD (3) · Bilal Omer, MD (2) · Brosgart C (2) · Daniele Lilleri, MD (2) · Dankner W (2) · Douglas Jabs, MD (2) · Feinberg J (2) · Hardy WD (2) · Hirsch M (2) · Jacobson M (2) · Jacques Galipeau, MD (2)
PMID 38700045, PMID 39807668, PMID 31042791, PMID 20353469, PMID 23196955, PMID 30596974, PMID 32504089, PMID 36298700, PMID 38190492, PMID 38324766, PMID 10204198, PMID 10996112, PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 16192248, PMID 16750653, PMID 16780548, PMID 17579921, PMID 17617198, PMID 17919618, PMID 18285548, PMID 19297572, PMID 19443656, PMID 19632953, PMID 19738014, PMID 19766534, PMID 20388893, PMID 20547904, PMID 20564615, PMID 21216835, PMID 21288834, PMID 21345642, PMID 21414843, PMID 21481708, PMID 21502083, PMID 21631323, PMID 21719601, PMID 22114962, PMID 22402037, PMID 22865914, PMID 23204178, PMID 23236375, PMID 23297260, PMID 23418272, PMID 23593305, PMID 23687088, PMID 23783429, PMID 24066743
2018 (4), 2017 (3), 2023 (3), R01CA077544 (3), U10EY008057 (3), P30CA033572 (2), 2005 (1), 2008 (1), 2015 (1), 2019 (1), 2025 (1), M01RR000036 (1), N01AI30025 (1), P01CA030206 (1), P01HL086773 (1)